IQVIA Holdings Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mediterranean Transcript
Good afternoon, everybody. I hope you enjoyed a nice lunch. I see that people are still trickling. We'll give them a moment. But as they come in, I will start by introducing myself. I'm Tom Baker. I come from the IQVIA Consulting group in -- I'm based in Basel. I have been asked to facilitate a discussion today about, in particular, the reimbursement challenges, the pricing challenges and overall, the market access landscape for novel therapies, ATMP cell and gene therapies. I know that was a topic this morning as well, and so hopefully, we won't cover the same ground. But I do think this is emerging as one of the most important topics facing this part of the industry given the sheer cost of some of the therapies and the inability of most payers to actually wholly value them in the systems that they have built for small molecules for chronic care therapies.
So today we want to dig into some of these challenges. And we have a panel today of 3 people who bring a lot of expertise in navigating this, both having
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
